ANI Pharmaceuticals financials
$72.62−2.95%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 | Q3 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $266.0M | $237.5M | $247.1M | $227.8M | $211.4M | $197.1M | $190.6M | $148.3M | $138.0M | $137.4M | $131.7M | $131.8M |
| Gross profit | $165.9M | $143.9M | $146.8M | $134.4M | $136.8M | $124.1M | $110.3M | $85.3M | $80.3M | $88.3M | $78.2M | $83.7M |
| Gross margin | 62.4% | 60.6% | 59.4% | 59.0% | 64.7% | 62.9% | 57.9% | 57.5% | 58.2% | 64.2% | 59.4% | 63.5% |
| Operating income | $40.5M | $38.9M | $34.9M | $36.5M | $13.9M | $26.2M | -$4.4M | -$20.5M | $5.2M | $15.0M | $6.7M | $17.9M |
| Net income | $23.0M | $27.4M | $25.4M | $23.8M | $7.3M | $13.7M | -$10.7M | -$24.6M | -$2.7M | $17.8M | $699.0K | $8.6M |
| Net margin | 8.6% | 11.6% | 10.3% | 10.4% | 3.5% | 7.0% | −5.6% | −16.6% | −2.0% | 13.0% | 0.5% | 6.6% |
| Diluted EPS | $1.05 | $1.28 | $1.08 | $1.13 | $0.36 | $0.69 | $-0.56 | $-1.27 | $-0.14 | $0.82 | $0.04 | $0.45 |
| EBITDA | $60.1M | $59.8M | $57.5M | $59.9M | $37.2M | $49.1M | $25.8M | -$4.8M | $19.9M | $29.7M | $8.7M | $30.6M |
| Operating cash flow | $56.7M | $58.4M | $30.4M | $44.1M | $75.8M | $35.0M | $15.9M | $12.5M | $17.5M | $18.2M | $44.7M | $32.2M |
| Free cash flow | $53.6M | $52.3M | $29.1M | $38.0M | $71.8M | $32.5M | $13.5M | $7.7M | $13.1M | $13.6M | $42.5M | $30.4M |
| Diluted shares | 21.9M | 21.5M | 23.5M | 21.1M | 20.3M | 20.0M | 19.1M | 19.4M | 19.3M | 19.4M | 19.3M | 19.1M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $360.2M | $311.2M | $285.6M | $262.6M | $217.8M | $149.8M |
| Short-term investments | $15.6M | $14.9M | $9.1M | $8.9M | $5.7M | $5.4M |
| Total debt | $610.5M | $613.8M | $617.0M | $312.9M | $314.7M | $622.8M |
| Total assets | $1.49B | $1.42B | $1.44B | $1.41B | $1.34B | $1.29B |
| Total liabilities | $896.9M | $859.7M | $899.7M | $902.3M | $881.4M | $849.0M |
| Shareholders' equity | $597.2M | $562.3M | $540.7M | $505.8M | $436.8M | $418.6M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology